C. B. Pratt, Ongoing clinical studies of ifosfamide for pediatric cancer in the United States, Semin Oncol. juin, vol.23, issue.3, pp.84-90, 1996.

P. A. Voûte, H. Van-den-berg, H. Behrendt, E. Michiels, and J. De-kraker, Ifosfamide in the treatment of pediatric malignancies, Semin Oncol. juin, vol.23, issue.3, pp.8-11, 1996.

M. E. Heim, R. Fiene, E. Schick, E. Wolpert, and W. Queisser, Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma, J Cancer Res Clin Oncol, vol.100, issue.1, pp.113-119, 1981.

C. B. Pratt, A. A. Green, M. E. Horowitz, W. H. Meyer, E. Etcubanas et al., Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna, J Clin Oncol Off J Am Soc Clin Oncol. août, vol.4, issue.8, pp.1253-61, 1986.

M. Zalupski, L. H. Baker, and . Ifosfamide, J Natl Cancer Inst. 15 juin, vol.80, issue.8, pp.556-66, 1988.

N. R. Anderson and D. S. Tandon, Ifosfamide extrapyramidal neurotoxicity. Cancer. 1 juill, vol.68, issue.1, pp.72-77, 1991.

A. R. Turner, Methylene Blue for the Treatment and Prophylaxis of Ifosfamide-induced Encephalopathy, Clin Oncol, vol.15, issue.7, pp.435-444, 2003.

C. A. Meanwell, A. E. Blake, K. A. Kelly, L. Honigsberger, and G. Blackledge, Prediction of ifosfamide/mesna associated encephalopathy, Eur J Cancer Clin Oncol. juill, vol.22, issue.7, pp.815-824, 1986.

T. Ajithkumar, C. Parkinson, F. Shamshad, and M. P. Ifosfamide, Clin Oncol R Coll Radiol G B. mars, vol.19, issue.2, pp.108-122, 2007.

B. Filhon, B. Lacarra, C. Hervouet, M. Jaffray, P. Schneider et al., Ifosfamideinduced encephalopathy due to a novel formulation of ifosfamide, Pediatr Blood Cancer. févr, vol.63, issue.2, pp.372-375, 2016.

. Ansm, Enquête de pharmacovigilance portant sur les effets indésirables neurologiques centraux de type encéphalopathie sous ifosfamide -HOLOXAN ® , IFOSFAMIDE EG ®, 2015.

G. Ginsberg, D. Hattis, and B. Sonawane, Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants, Toxicol Appl Pharmacol. 15 juill, vol.198, issue.2, pp.164-83, 2004.

J. Pelgrims, D. Vos, F. Van-den-brande, J. Schrijvers, D. Prové et al., Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature, Br J Cancer. janv, vol.82, issue.2, pp.291-295, 2000.

M. P. Goren, R. K. Wright, C. B. Pratt, and F. E. Pell, Dechloroethylation of ifosfamide and neurotoxicity, Lancet Lond Engl, vol.22, issue.8517, pp.1219-1239, 1986.

A. Küpfer, C. Aeschlimann, and T. Cerny, Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy, Eur J Clin Pharmacol, vol.50, issue.4, pp.249-52, 1996.

V. Kurowski, T. Cerny, A. Küpfer, and T. Wagner, Metabolism and pharmacokinetics of oral and intravenous ifosfamide, J Cancer Res Clin Oncol, vol.117, issue.4, pp.148-153, 1991.

B. H. Lauterburg, T. Nguyen, B. Hartmann, E. Junker, A. Küpfer et al., Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy, Cancer Chemother Pharmacol, vol.35, issue.2, pp.132-138, 1994.

T. M. Visarius, J. W. Stucki, and B. H. Lauterburg, Stimulation of respiration by methylene blue in rat liver mitochondria, FEBS Lett. 21 juill, vol.412, issue.1, pp.157-60, 1997.

P. Nicolao and B. Giometto, Neurological toxicity of ifosfamide, Oncology, vol.65, issue.2, pp.11-17, 2003.

T. M. Visarius, J. W. Stucki, and B. H. Lauterburg, Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats, J Pharmacol Exp Ther. mai, vol.289, issue.2, pp.820-824, 1999.

M. S. Highley, G. Momerency, D. Sawyers, E. Bruijn, H. Prenen et al., The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide, J Anal Oncol. 12 févr, vol.4, issue.1, pp.13-23, 2015.

J. P. Curtin, P. P. Koonings, M. Gutierrez, J. B. Schlaerth, and C. P. Morrow, Ifosfamide-induced neurotoxicity, Gynecol Oncol. sept, vol.42, issue.3, pp.193-199, 1991.

C. A. Meanwell, K. A. Kelly, and G. Blackledge, Avoiding ifosfamide/mesna encephalopathy, Lancet Lond Engl. 16 août, vol.2, issue.8503, p.406, 1986.

C. B. Pratt, M. P. Goren, W. H. Meyer, B. Singh, and R. K. Dodge, Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors, J Clin Oncol Off J Am Soc Clin Oncol. août, vol.8, issue.8, pp.1399-401, 1990.

A. H. Szabatura, F. Cirrone, C. Harris, A. M. Mcdonnell, Y. Feng et al., An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. juin, vol.21, issue.3, pp.188-93, 2015.

C. Dufour, J. Grill, P. Sabouraud, C. Behar, M. Munzer et al.,

, Arch Pediatr Organe Off Soc Francaise Pediatr. févr, vol.13, issue.2, pp.140-145, 2006.

J. E. Howell, A. H. Szabatura, H. Seung, A. Nesbit, and S. A. , Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. sept, vol.14, issue.3, pp.157-62, 2008.

A. Jarkowski, Possible contribution of aprepitant to ifosfamide-induced neurotoxicity, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 déc, vol.65, issue.23, pp.2229-2260, 2008.

C. Rieger, M. Fiegl, J. Tischer, H. Ostermann, and X. Schiel, Incidence and severity of ifosfamide-induced encephalopathy, Anticancer Drugs. avr, vol.15, issue.4, pp.347-50, 2004.

T. J. Perren, R. C. Turner, and I. E. Smith, Encephalopathy with rapid infusion ifosfamide/mesna, Lancet Lond Engl. 14 févr, vol.1, issue.8529, pp.390-391, 1987.

S. W. Watkin, D. J. Husband, J. A. Green, and H. M. Warenius, Ifosfamide encephalopathy: a reappraisal, Eur J Cancer Clin Oncol. sept, vol.25, issue.9, pp.1303-1313, 1989.

A. K. Mccallum, Ifosfamide/mesna encephalopathy, Lancet Lond Engl. 25 avr, vol.1, issue.8539, p.987, 1987.

A. M. Feyissa and S. Tummala, Ifosfamide related encephalopathy: the need for a timely EEG evaluation, J Neurol Sci. 15 janv, vol.336, issue.1-2, pp.109-121, 2014.

B. M. Cantwell and A. L. Harris, Ifosfamide/mesa and encephalopathy, Lancet Lond Engl. 30 mars, vol.1, issue.8431, p.752, 1985.

A. Küpfer, C. Aeschlimann, B. Wermuth, and T. Cerny, Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue, Lancet Lond Engl. 26 mars, vol.343, issue.8900, pp.763-767, 1994.

A. Verdeguer, V. Castel, C. Esquembre, J. Ferris, J. M. Fernandez et al., Fatal encephalopathy with ifosfamide/mesna, Pediatr Hematol Oncol, vol.6, issue.4, pp.383-388, 1989.

J. M. Ferrero, P. Eftekari, R. Largillier, G. Dreyfus, and M. Namer, Bull Cancer (Paris). juill, vol.82, issue.7, pp.598-607, 1995.

B. Kasper, C. Harter, J. Meissner, F. Bellos, F. Krasniqi et al., Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with highdose ifosfamide? Support Care Cancer Off J Multinatl Assoc Support Care Cancer, mars, vol.12, issue.3, pp.205-212, 2004.

, Küpfer et al. sont les premiers auteurs à avoir évoqué son efficacité suite à la mise en évidence d'un excès d'excrétion urinaire d'acide glutarique chez une patiente présentant une EII, L'utilisation du BM est conseillée par de nombreux auteurs mais il n'existe aucune recommandation nationale ni étude contrôlée randomisée pour appuyer cette hypothèse

, D'autres mécanismes d'action du BM ont été évoqués depuis, ceux-ci sont résumés dans la figure 4

, Certaines équipes ne rapportent aucune récidive. (24,44,45) Au contraire d'autres équipes, décrivent des récidivent avec parfois même une évolution vers une forme plus sévère

É. Dans-notre, le traitement par ifosfamide a été repris dans la quasi-totalité des cas, { l'exception d'un patient dans le groupe Ifosfamide EG ® ayant présenté des convulsions généralisées répétées. Les modalités de reprises sont majoritairement l'allongement de la durée de perfusion >

, Le bleu de méthylène a été utilisé de manière préventive pour 1 patient dans le groupe

, Holoxan ® et 4 patients dans le groupe Ifosfamide EG ®

, Nous avons noté 4 cas sur 7 de récurrence d'EII dans le groupe Holoxan ® et 5 cas sur, p.14

E. G. Dans-le-groupe-ifosfamide and . Dont-une-récurrence-multiple,

L. , EII ne s'est aggravée dans aucun cas de récidive. Par ailleurs, 1 enfant sur 7 dans le groupe Holoxan ® et 5 sur 14 dans le groupe traité par

E. Ifosfamide, un relais de traitement par Endoxan ® . Cette tendance étant peut être liée à une plus grande appréhension { l'utilisation de l'Ifosfamide EG ® depuis qu'un risque augmenté de complications a été suspecté

, Les facteurs prédisposants cliniques ou pharmacologiques pouvant favoriser le développement d'une encéphalopathie induite par ifosfamide ont été décrits principalement chez les adultes. Les plus fréquemment cités dans la littérature sont l'âge, la dose cumulée d'ifosfamide, l'administration antérieure d'ifosfamide, l'administration concomitante d'autres médicaments, l'insuffisance rénale, l'atteinte pelvienne notamment pour les sarcomes

E. B. Krumbhaar, RÔLE OF THE BLOOD AND THE BONE MARROW IN CERTAIN FORMS OF GAS POISONING: I. PERIPHERAL BLOOD CHANGES AND THEIR SIGNIFICANCE, J Am Med Assoc. 4 janv, vol.72, issue.1, p.39, 1919.

D. M. Noll, T. M. Mason, and P. S. Miller, Formation and Repair of Interstrand Cross-Links in DNA, Chem Rev. févr, vol.106, issue.2, pp.277-301, 2006.

K. L. Dechant, R. N. Brogden, T. Pilkington, and D. Faulds, Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer, Drugs. sept, vol.42, issue.3, pp.428-67, 1991.

H. O. Klein, P. Dias-wickramanayake, C. Coerper, E. Christian, J. Pohl et al., Highdose ifosfamide and mesna as continuous infusion over five days-a phase I/II trial, Cancer Treat Rev. sept, vol.10, pp.167-73, 1983.

C. Manegold, P. Drings, A. Pawinski, M. A. Lentz, M. Van-glabbeke et al., Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group, Ann Oncol Off J Eur Soc Med Oncol. août, vol.7, issue.6, pp.637-646, 1996.

G. P. Kaijser, J. H. Beijnen, A. Bult, and W. J. Underberg, Ifosfamide metabolism and pharmacokinetics (review), Anticancer Res. avr, vol.14, issue.2A, pp.517-548, 1994.

M. S. Highley, D. Schrijvers, A. T. Van-oosterom, P. G. Harper, G. Momerency et al., Activated oxazaphosphorines are transported predominantly by erythrocytes, Ann Oncol Off J Eur Soc Med Oncol, vol.8, issue.11, pp.1139-1183, 1997.

S. M. Yule, L. Price, A. D. Pearson, and A. V. Boddy, Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children, Clin Cancer Res Off J Am Assoc Cancer Res, vol.3, issue.11, pp.1985-92, 1997.

P. Beaune,

, Therapie. déc, vol.48, issue.6, pp.521-527, 1993.

M. Furlanut and L. Franceschi, Pharmacology of Ifosfamide. Oncology, vol.65, pp.2-6, 2003.

D. L. Hill, W. R. Laster, M. C. Kirk, S. El-dareer, and R. F. Struck, Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite, Cancer Res. mai, vol.33, issue.5, pp.1016-1038, 1973.

A. V. Boddy, M. English, A. D. Pearson, J. R. Idle, and R. Skinner, Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics, Eur J Cancer Oxf Engl, vol.32, issue.7, pp.1179-84, 1990.

G. P. Kaijser, D. Kraker, J. Bult, A. Underberg, W. J. Beijnen et al., Pharmacokinetics of ifosfamide and some metabolites in children, Anticancer Res. juin, vol.18, issue.3B, pp.1941-1950, 1998.

T. Kerbusch, J. Kraker, . De, H. J. Keizer, J. Putten et al., Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites. Clin Pharmacokinet. 1 janv, vol.40, issue.1, pp.41-62, 2001.

K. Norpoth, H. Raidt, U. Witting, G. Müller, and R. Norpoth, Side chain oxidation of ifosfamide in man, Klin Wochenschr, vol.15, issue.22, pp.1075-1081, 1975.

C. Aeschlimann, T. Cerny, and A. Küpfer, Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue, Drug Metab Dispos Biol Fate Chem. déc, vol.24, issue.12, pp.1336-1345, 1996.

R. Loebstein and G. Koren, Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors, Pediatrics. juin, vol.101, issue.6, p.8, 1998.

C. Loqueviel, M. Malet-martino, and M. R. 13c-nmr, Cchloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism, Cell Mol Biol Noisy--Gd Fr. juill, vol.43, issue.2, pp.773-82, 1997.

N. E. Sladek, Metabolism of oxazaphosphorines, Pharmacol Ther, vol.37, issue.3, pp.301-55, 1988.

T. Kerbusch, R. A. Mathôt, H. J. Keizer, G. P. Kaijser, J. H. Schellens et al., Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites, Drug Metab Dispos Biol Fate Chem. juill, vol.29, issue.7, pp.967-75, 2001.

B. M. Bryant, M. Jarman, H. T. Ford, and I. E. Smith, Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma, Lancet Lond Engl. 27 sept, vol.2, issue.8196, pp.657-666, 1980.

T. Ajithkumar, C. Parkinson, F. Shamshad, and M. P. Ifosfamide, Clin Oncol R Coll Radiol G B. mars, vol.19, issue.2, pp.108-122, 2007.

A. Verdeguer, V. Castel, C. Esquembre, J. Ferris, J. M. Fernandez et al., Fatal encephalopathy with ifosfamide/mesna, Pediatr Hematol Oncol, vol.6, issue.4, pp.383-388, 1989.

C. B. Pratt, A. A. Green, M. E. Horowitz, W. H. Meyer, E. Etcubanas et al., Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna, J Clin Oncol Off J Am Soc Clin Oncol. août, vol.4, issue.8, pp.1253-61, 1986.

C. S. Bruggers, H. S. Friedman, R. Tien, and R. Delong, Cerebral atrophy in an infant following treatment with ifosfamide, Med Pediatr Oncol, vol.23, issue.4, pp.380-383, 1994.

A. Shuper, J. Stein, J. Goshen, L. Kornreich, I. Yaniv et al., Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication, J Child Neurol. juill, vol.15, issue.7, pp.481-484, 2000.

A. R. Turner, Methylene Blue for the Treatment and Prophylaxis of Ifosfamideinduced Encephalopathy, Clin Oncol, vol.15, issue.7, pp.435-444, 2003.

C. A. Meanwell, A. E. Blake, K. A. Kelly, L. Honigsberger, and G. Blackledge, Prediction of ifosfamide/mesna associated encephalopathy, Eur J Cancer Clin Oncol. juill, vol.22, issue.7, pp.815-824, 1986.

A. M. Feyissa and S. Tummala, Ifosfamide related encephalopathy: the need for a timely EEG evaluation, J Neurol Sci. 15 janv, vol.336, issue.1-2, pp.109-121, 2014.

J. E. Howell, A. H. Szabatura, H. Seung, A. Nesbit, and S. A. , Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. sept, vol.14, issue.3, pp.157-62, 2008.

A. Jarkowski, Possible contribution of aprepitant to ifosfamide-induced neurotoxicity, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 déc, vol.65, issue.23, pp.2229-2260, 2008.

C. Dufour, J. Grill, P. Sabouraud, C. Behar, M. Munzer et al., Arch Pediatr Organe Off Soc Francaise Pediatr. févr, vol.13, issue.2, pp.140-145, 2006.

K. A. David and J. Picus, Evaluating risk factors for the development of ifosfamide encephalopathy, Am J Clin Oncol. juin, vol.28, issue.3, pp.277-80, 2005.

A. Küpfer, C. Aeschlimann, B. Wermuth, and T. Cerny, Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue, Lancet Lond Engl. 26 mars, vol.343, issue.8900, pp.763-767, 1994.

J. P. Curtin, P. P. Koonings, M. Gutierrez, J. B. Schlaerth, and C. P. Morrow, Ifosfamide-induced neurotoxicity, Gynecol Oncol. sept, vol.42, issue.3, pp.193-199, 1991.

J. M. Buesa, P. García-teijido, R. Losa, and J. Fra, Treatment of Ifosfamide Encephalopathy with Intravenous Thiamin, Clin Cancer Res, vol.9, issue.12, pp.4636-4643, 2003.

B. Filhon, B. Lacarra, C. Hervouet, M. Jaffray, P. Schneider et al., Ifosfamideinduced encephalopathy due to a novel formulation of ifosfamide, Pediatr Blood Cancer. févr, vol.63, issue.2, pp.372-375, 2016.

G. Ginsberg, D. Hattis, and B. Sonawane, Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants, Toxicol Appl Pharmacol. 15 juill, vol.198, issue.2, pp.164-83, 2004.

P. Nicolao and B. Giometto, Neurological toxicity of ifosfamide, Oncology, vol.65, issue.2, pp.11-17, 2003.

T. M. Visarius, J. W. Stucki, and B. H. Lauterburg, Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats, J Pharmacol Exp Ther. mai, vol.289, issue.2, pp.820-824, 1999.

J. Y. Chatton, J. R. Idle, C. B. Vågbø, and P. J. Magistretti, Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons, J Pharmacol Exp Ther. déc, vol.299, issue.3, pp.1161-1169, 2001.

. Ansm, Enquête de pharmacovigilance portant sur les effets indésirables neurologiques centraux de type encéphalopathie sous ifosfamide -HOLOXAN ® , IFOSFAMIDE EG ®, 2015.

C. Rieger, M. Fiegl, J. Tischer, H. Ostermann, and X. Schiel, Incidence and severity of ifosfamide-induced encephalopathy, Anticancer Drugs. avr, vol.15, issue.4, pp.347-50, 2004.

C. B. Pratt, M. P. Goren, W. H. Meyer, B. Singh, and R. K. Dodge, Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors, J Clin Oncol Off J Am Soc Clin Oncol. août, vol.8, issue.8, pp.1399-401, 1990.

K. H. Antman, L. Ryan, A. Elias, D. Sherman, and H. E. Grier, Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma, J Clin Oncol Off J Am Soc Clin Oncol. janv, vol.7, issue.1, pp.126-157, 1989.